KRAS and lung carcinoma: More extensive analysis of PD-L1 surface expression on multiple KRAS mutant lung cancer cell lines, both human and murine, revealed generally consistent PD-L1 downregulation after MEK and PI3K inhibition, suggesting that this regulatory pathway is of broad significance (Figure S1H).